Vivos Therapeutics (VVOS) Total Debt (2019 - 2026)

Vivos Therapeutics' (VVOS) quarterly Total Debt came in at $7.7 million in Q1 2026, down 12.53% on a QoQ basis from $8.8 million in Q4 2025.

Vivos Therapeutics (VVOS) Total Debt (2019 - 2026) Analysis & Trends

Vivos Therapeutics (VVOS) has 5 years of Total Debt data on file, last reported at $7.7 million in Q1 2026.

On a quarterly basis, Total Debt changed N/A year-over-year to $7.7 million in Q1 2026; TTM through Mar 2026 was $7.7 million, a N/A change from a year earlier, with the FY2025 full-year figure at $8.8 million, changed N/A from the prior year.
Total Debt for Q1 2026 stood at $7.7 million, down from $8.8 million in the prior quarter.
Over the last five years, Total Debt for VVOS reached as high as $8.8 million in Q4 2025 and fell as low as $7.7 million in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Debt (Qtr)
1	Abbott Laboratories	201.40 Bn	194.75 Bn	6.27 Bn	34.05 Bn
2	Stryker	122.29 Bn	119.41 Bn	3.81 Bn	14.72 Bn
3	Medtronic	105.01 Bn	96.40 Bn	6.41 Bn	27.96 Bn
4	Boston Scientific	64.81 Bn	63.59 Bn	3.61 Bn	11.03 Bn
5	Edwards Lifesciences	55.28 Bn	51.60 Bn	1.29 Bn	598.50 Mn
6	Dexcom	29.06 Bn	27.94 Bn	750.30 Mn	-
7	Koninklijke Philips	29.02 Bn	25.93 Bn	2.07 Bn	9.48 Bn
8	GE HealthCare Technologies	28.27 Bn	26.20 Bn	1.98 Bn	10.14 Bn
9	Smith & Nephew	25.80 Bn	25.22 Bn	-	3.18 Bn
10	Vivos Therapeutics	3.62 Mn	1.38 Mn	3.06 Mn	7.72 Mn

Download Data